Erythropoiesis-Stimulating Agents (ESAs) are prescribed to individuals who are anaemic, such as post renal (kidney) transplantation patients and patients on chemotherapies. The FDA has released a strengthened warning about dosing of ESAs. The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

    The FDA and the manufacturer of these products have agreed on revised product labeling that includes updated warnings, a new boxed warning, and modifications to the dosing instructions. The new boxed warning advises physicians to monitor red blood cell levels (hemoglobin) and to adjust the ESA dose to maintain the lowest hemoglobin level needed to avoid the need for blood transfusions. Physicians and patients should carefully weigh the risks of ESAs against transfusion risks.